1. Home
  2. Vol 19, No 2 (2025)
  3. Lubis

The Efficacy and Safety of Ixazomib for Newly Diagnosed Multiple Myeloma (NDMM) and Refractory or Relapsed Multiple Myeloma (RRMM): An Updated Systematic Review

Ainun Basyiroh Lubis, Damai Santosa, Daniel Rizky, Kevin Tandarto, Ika Kartiyani, Vina Yunarvika, Desta Nur Ewika Ardini, Budi Setiawan, Eko Adhi Pangarsa, Catharina Suharti

Abstract


Background: Newly diagnosed multiple myeloma (NDMM) is a significant healthcare concern, comprising 1.8% of newly diagnosed cancers in the United States. Recent advancements in NDMM and refractory/relapsed multiple myeloma (RRMM) treatment, including novel agents like ixazomib, have improved patient outcomes. Ixazomib, an oral proteasome inhibitor, has shown promise in clinical trials, particularly in combination with lenalidomide and dexamethasone (IRd). This study aims to find the efficacy and safety profiles of ixazomib for NRMM and RRMM.

Methods: We conducted a systematic literature review using Scopus, PubMed, Google Scholar, and ProQuest databases, focusing on randomized controlled trials (RCTs) evaluating ixazomib’s efficacy and safety in NDMM and RRMM treatment. Eligibility criteria included studies published within the last 3 years reporting data on ixazomib in NDMM and RRMM patients. Quality assessment utilized the Cochrane Risk of Bias tool for RCTs.

Results: The review identified three studies from 2021–2023 demonstrating ixazomib’s efficacy and safety in MM treatment across various patient groups. Benefits included improved progression-free survival (PFS) in non-transplant NDMM, significant PFS advantage in relapsed/ refractory MM, and efficacy in transplant-ineligible NDMM induction regimens.

Conclusion: Ixazomib emerges as a well-tolerated maintenance therapy offering significant PFS advantages in NDMM and RRMM, irrespective of age or frailty status. Future research, including multicenter studies, is warranted to further elucidate ixazomib’s role in MM management.


Keywords


xazomib, multiple myeloma, systematic review

Full Text: View | Download

DOI: 10.33371/ijoc.v19i2.1241

Article Metrics

Abstract View: 564,
PDF Download: 242
             

References


Nikolaou A, Hogea C, Samyshkin Y, et al. An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure. Value in Health. 2022 Dec;25(12):1977–85.

Ludwig H, Novis Durie S, Meckl A, et al. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020 Sep 1;25(9):e1406–13.

Horigome Y, Iino M, Harazaki Y, et al. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Ann Hematol. 2024 Feb 11;103(2):475–88.

Ding K, Yu H, Shao YY, et al. Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China. Cancer Manag Res. 2020 Sep;Volume 12:8935–41.

Shafqat M, Jamil F, Shah Z, et al. A systematic review and meta-analysis: efficacy and toxicity profile of ixazomib for treatment of multiple myeloma. Blood. 2018 Nov 29;132:5639.

Lai E, Soon YY, Lee AR, et al. Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood. 2021 Nov 23;138:3776.

Bringhen S, Pour L, Benjamin R, et al. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):491–504.

Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology. 2021 Aug 1;39(22):2430–42.

Mina R, Falcone AP, Bringhen S, Liberati AM, Pescosta N, Petrucci MT, et al. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. Blood Cancer J. 2021 Dec 7;11(12).

Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, et al. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study. Ann Hematol. 2023 Aug 10;102(8):2137–51.

Azab AK, Muz B, Ghazarian R, Ou M, Luderer M, Kusdono H. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther. 2016 Jan;217.

Larocca A, Corradini P, Mina R, Cascavilla N, Liberati AM, Pescosta N, et al. Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study. Blood. 2019 Nov 13;134(Supplement_1):3195–3195.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.